Compare CMRE & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | AGIO |
|---|---|---|
| Founded | 1974 | 2007 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | CMRE | AGIO |
|---|---|---|
| Price | $16.04 | $27.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $12.00 | ★ $37.63 |
| AVG Volume (30 Days) | 437.9K | ★ 708.3K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $75.68 |
| Revenue Next Year | N/A | $167.63 |
| P/E Ratio | $5.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.63 | $22.24 |
| 52 Week High | $17.91 | $46.00 |
| Indicator | CMRE | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 46.37 |
| Support Level | $15.21 | $26.48 |
| Resistance Level | $16.67 | $29.49 |
| Average True Range (ATR) | 0.57 | 1.13 |
| MACD | -0.16 | -0.17 |
| Stochastic Oscillator | 7.21 | 25.09 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.